Assessing cognitive function in bipolar disorder: Challenges and recommendations for clinical trial design

Journal of Clinical Psychiatry

Volumn 76, Issue 3, 2015, Pages e342-e350

  Burdick, Katherine E ^a,b   Ketter, Terence A ^c   Goldberg, Joseph F ^a   Calabrese, Joseph R ^d  

^a Departments of Psychiatry and Behavioral Sciences   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CARBAMAZEPINE; LAMOTRIGINE; LITHIUM CARBONATE; PRAMIPEXOLE; SEROTONIN UPTAKE INHIBITOR; TOPIRAMATE; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROIC ACID;

AGITATION; AKATHISIA; ANXIETY; ARTICLE; ATTENTION DEFICIT DISORDER; BIPOLAR DEPRESSION; BIPOLAR DISORDER; BIPOLAR I DISORDER; BIPOLAR II DISORDER; CLINICAL TRIAL (TOPIC); COGNITION; COGNITIVE DEFECT; COMORBIDITY; FUNCTIONAL ASSESSMENT; FUNCTIONAL STATUS; HUMAN; NEUROPSYCHOLOGICAL TEST; POLYPHARMACY; PRIORITY JOURNAL; QUALITY OF LIFE; SAMPLE SIZE; SCHIZOPHRENIA; SEDATION; SOMNOLENCE; STUDY DESIGN; UNSPECIFIED SIDE EFFECT; COGNITION DISORDERS; COMPLICATION; CONSENSUS; METHODOLOGY; PRACTICE GUIDELINE; STANDARDS;

BIPOLAR DISORDER; CLINICAL TRIALS AS TOPIC; COGNITION DISORDERS; CONSENSUS; GUIDELINES AS TOPIC; HUMANS; RESEARCH DESIGN;

EID: 84930229498     PISSN: 01606689     EISSN: 15552101     Source Type: Journal    
DOI: 10.4088/JCP.14cs09399     Document Type: Article

References (65)

1. Bowden CL, Brugger AM, Swann AC, et al; The Depakote Mania Study Group. Efficacy of divalproex vs lithium and placebo in the treatment of mania. JAMA. 1994;271(12):918-924. doi:10.101/jama.194.035103604034
2. Calabrese JR, Hirschfeld RM, Frye MA, et al. Impact of depressive symptoms compared with manic symptoms in bipolar disorder: results of a US community-based sample. J Clin Psychiatry. 2004;65(11):1499-1504. doi:10.408/JCP.v65n109
3. Judd LL, Akiskal HS, Schettler PJ, et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry. 2002;59(6):530-537. doi:10.101/archpsyc.59.6.530
4. Judd LL, Akiskal HS, Schettler PJ, et al. The comparative clinical phenotype and long term longitudinal episode course of bipolar I and II: a clinical spectrum or distinct disorders? J Affect Disord. 2003;73(1-2):19-32. doi:10.1016/S0165-0327(02)0324-5
5. Judd LL, Akiskal HS, Schettler PJ, et al. Psychosocial disability in the course of bipolar I and II disorders: a prospective, comparative, longitudinal study. Arch Gen Psychiatry. 2005;62(12):1322-1330. doi:10.101/archpsyc.62.12.132
6. Judd LL, Schettler PJ, Solomon DA, et al. Psychosocial disability and work role function compared across the long-term course of bipolar I, bipolar II and unipolar major depressive disorders. J Affect Disord. 2008;108(1-2):49-58. doi:10.1016/j.jad.207.06.014
7. Bowden CL, Perlis RH, Thase ME, et al. Aims and results of the NIMH systematic treatment enhancement program for bipolar disorder (STEP-BD). CNS Neurosci Ther. 2012;18(3):243-249. doi:10.1/j.175-5949.201.0257.x
8. Lim CS, Baldessarini RJ, Vieta E, et al. Longitudinal neuroimaging and neuropsychological changes in bipolar disorder patients: review of the evidence. Neurosci Biobehav Rev. 2013;37(3):418-435. doi:10.1016/j.neubiorev.2013.01.03
9. Judd LL, Akiskal HS, Schettler PJ, et al. A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch Gen Psychiatry. 2003;60(3):261-269. doi:10.101/archpsyc.60.3.261
10. Daban C, Martinez-Aran A, Torrent C, et al. Specificity of cognitive deficits in bipolar disorder versus schizophrenia: a systematic review. Psychother Psychosom. 2006;75(2):72-84. doi:10.159/090891
11. Kurtz MM, Gerraty RT. A meta-analytic investigation of neurocognitive deficits in bipolar illness: profile and effects of clinical state. Neuropsychology. 2009;23(5):551-562. doi:10.1037/a01627
12. Arts B, Jabben N, Krabbendam L, et al. Meta-analyses of cognitive functioning in euthymic bipolar patients and their first-degree relatives. Psychol Med. 2008;38(6):771-785. doi:10.1017/S0329170701675
13. Robinson LJ, Thompson JM, Gallagher P, et al. A meta-analysis of cognitive deficits in euthymic patients with bipolar disorder. J Affect Disord. 2006;93(1-3):105-115. doi:10.1016/j.jad.206.02.016
14. Torres IJ, Boudreau VG, Yatham LN. Neuropsychological functioning in euthymic bipolar disorder: a meta-analysis. Acta Psychiatr Scand suppl. 2007;116(434):17-26. doi:10.1/j.160-047.207.0105.x
15. Harvey PD, Wingo AP, Burdick KE, et al. Cognition and disability in bipolar disorder: lessons from schizophrenia research. Bipolar Disord. 2010;12(4):364-375. doi:10.1/j.139-5618.2010.0831.x
16. Zammit S, Allebeck P, David AS, et al. A longitudinal study of premorbid IQ Score and risk of developing schizophrenia, bipolar disorder, severe depression, and other nonaffective psychoses. Arch Gen Psychiatry. 2004;61(4):354-360. doi:10.101/archpsyc.61.4.354
17. Iosifescu DV. The relation between mood, cognition and psychosocial functioning in psychiatric disorders. Eur Neuropsychopharmacol. 2012;22(suppl 3):S499-S504. doi:10.1016/j.euroneuro.2012.08.02
18. Rosa AR, Bonn CM, Vquez GH, et al. Functional impairment in bipolar II disorder: is it as disabling as bipolar I? J Affect Disord. 2010;127(1-3):71-76. doi:10.1016/j.jad.2010.05.014
19. SolB, Martez-Ar A, Torrent C, et al. Are bipolar II patients cognitively impaired? a systematic review. Psychol Med. 2011;41(9):1791-1803. doi:10.1017/S0329171018
20. Bora E, Yel M, Pantelis C, et al. Meta-analytic review of neurocognition in bipolar II disorder. Acta Psychiatr Scand. 2011;123(3):165-174. doi:10.1/j.160-047.2010.01638.x
21. Bora E, Yel M, Pantelis C. Neurocognitive markers of psychosis in bipolar disorder: a meta-analytic study. J Affect Disord. 2010;127(1-3):1-9.
22. Green MF, Kern RS, Braff DL, et al. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the right stuff? Schizophr Bull. 2000;26(1):119-136. doi:10.1093/oxfordjournals.schbul.a03430
23. Shamsi S, Lau A, Lencz T, et al. Cognitive and symptomatic predictors of functional disability in schizophrenia. Schizophr Res. 2011;126(1-3):257-264. doi:10.1016/j.schres.2010.08.07
24. Bowie CR, Depp C, McGrath JA, et al. Prediction of real-world functional disability in chronic mental disorders: a comparison of schizophrenia and bipolar disorder. Am J Psychiatry. 2010;167(9):1116-1124. doi:10.176/api.ajp.2010.09101406
25. Burdick KE, Goldberg JF, Harrow M. Neurocognitive dysfunction and psychosocial outcome in patients with bipolar I disorder at 15-year follow-up. Acta Psychiatr Scand. 2010;122(6):499-506. doi:10.1/j.160-047.2010.01590.x
26. Green MF, Nuechterlein KH, Gold JM, et al. Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria. Biol Psychiatry. 2004;56(5):301-307. doi:10.1016/j.biopsych.204.06.023
27. Buchanan RW, Davis M, Goff D, et al. A summary of the FDA-NIMHMATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia. Schizophr Bull. 2005;31(1):5-19. doi:10.1093/schbul/sbi020
28. Buchanan RW, Keefe RS, Umbricht D, et al. The FDA-NIMH-MATRICS guidelines for clinical trial design of cognitive-enhancing drugs: what do we know 5 years later? Schizophr Bull. 2011;37(6):1209-1217. doi:10.1093/schbul/sbq038
29. Burdick KE, Goldberg TE, Cornblatt BA, et al. The MATRICS consensus cognitive battery in patients with bipolar I disorder. Neuropsychopharmacology. 2011;36(8):1587-1592. doi:10.1038/np.201.36
30. Pettinati HM, OBrien CP, Dundon WD. Current status of co-occurring mood and substance use disorders: a new therapeutic target. Am J Psychiatry. 2013;170(1):23-30. doi:10.176/api.ajp.2012.1201012
31. Lenze EJ, Dixon D, Mantella RC, et al. Treatment-related alteration of cortisol predicts change in neuropsychological function during acute treatment of late-life anxiety disorder. Int J Geriatr Psychiatry. 2012;27(5):454-462. doi:10.102/gps.2732
32. Basso MR, Lowery N, Neel J, et al. Neuropsychological impairment among manic, depressed, and mixed-episode inpatients with bipolar disorder. Neuropsychology. 2002;16(1):84-91. doi:10.1037/0894-4105.16.1.84
33. Bonn CM, Martez-Ar A, Torrent C, et al. Clinical and neurocognitive predictors of functional outcome in bipolar euthymic patients: a long-term, follow-up study. J Affect Disord. 2010;121(1-2):156-160. doi:10.1016/j.jad.209.05.014
34. Bonn CM, Gonzez-Pinto A, SolB, et al; CIBERSAM Functional Remediation Group. Verbal memory as a mediator in the relationship between subthreshold depressive symptoms and functional outcome in bipolar disorder. J Affect Disord. 2014;160:50-54. doi:10.1016/j.jad.2014.02.034
35. Keefe RS, Buchanan RW, Marder SR, et al. Clinical trials of potential cognitive-enhancing drugs in schizophrenia: what have we learned so far? Schizophr Bull. 2013;39(2):417-435. doi:10.1093/schbul/sbr153
36. Goldberg JF, Burdick KE. Cognitive side effects of anticonvulsants. J Clin Psychiatry. 2001;62(suppl 14):27-33.
37. Goldberg JF, Chengappa KN. Identifying and treating cognitive impairment in bipolar disorder. Bipolar Disord. 2009;11(suppl 2):123-137. doi:10.1/j.139-5618.209.0716.x
38. Wingo AP, Wingo TS, Harvey PD, et al. Effects of lithium on cognitive performance: a meta-analysis. J Clin Psychiatry. 2009;70(11):1588-1597. doi:10.408/JCP.08r04972
39. Lez-Jaramillo C, Lopera-Vquez J, Ospina-Duque J, et al. Lithium treatment effects on the neuropsychological functioning of patients with bipolar I disorder. J Clin Psychiatry. 2010;71(8):1055-1060. doi:10.408/JCP.08m04673yel
40. Mur M, Portella MJ, Martez-Ar A, et al. Neuropsychological profile in bipolar disorder: a preliminary study of monotherapy lithium-treated euthymic bipolar patients evaluated at a 2-year interval. Acta Psychiatr Scand. 2008;118(5):373-381. doi:10.1/j.160-047.208.01245.x
41. Daban C, Martez-Ar A, Torrent C, et al. Cognitive functioning in bipolar patients receiving lamotrigine: preliminary results. J Clin Psychopharmacol. 2006;26(2):178-181. doi:10.1097/01.jcp.020432.64390.f3
42. McIntyre RS, Konarski JZ. Tolerability profiles of atypical antipsychotics in the treatment of bipolar disorder. J Clin Psychiatry. 2005;66(suppl 3):28-36.
43. Manuel-Apolinar L, Meneses A. 8-OH-DPAT facilitated memory consolidation and increased hippocampal and cortical cAMP production. Behav Brain Res. 2004;148(1-2):179-184. doi:10.1016/S016-4328(03)0186-4
44. Biringer E, Rongve A, Lund A. A review of modern antidepressants effects on neurocognitive function. Curr Psychiatry Rev. 2009;5(3):164-174. doi:10.2174/15734097897137
45. McIntyre RS, Lophaven S, Olsen CK. A randomized, double-blind, placebocontrolled study of vortioxetine on cognitive function in depressed adults. Int J Neuropsychopharmacol. 2014;17(10):1557-1567. doi:10.1017/S1461457140546
46. Burdick KE, Braga RJ, Nnadi CU, et al. Placebo-controlled adjunctive trial of pramipexole in patients with bipolar disorder: targeting cognitive dysfunction. J Clin Psychiatry. 2012;73(1):103-112. doi:10.408/JCP.1m0729
47. Levine J, Chengappa KN, Brar JS, et al. Psychotropic drug prescription patterns among patients with bipolar I disorder. Bipolar Disord. 2000;2(2):120-130. doi:10.1034/j.139-5618.20.020205.x
48. Hassel S, Almeida JR, Kerr N, et al. Elevated striatal and decreased dorsolateral prefrontal cortical activity in response to emotional stimuli in euthymic bipolar disorder: no associations with psychotropic medication load. Bipolar Disord. 2008;10(8):916-927. doi:10.1/j.139-5618.208.0641.x
49. Martino DJ, Strejilevich SA, Scola M, et al. Heterogeneity in cognitive functioning among patients with bipolar disorder. J Affect Disord. 2008;109(1-2):149-156. doi:10.1016/j.jad.207.12.232
50. Burdick KE, Russo M, Frangou S, et al. Empirical evidence for discrete neurocognitive subgroups in bipolar disorder: clinical implications. Psychol Med. 2014;44(14):3083-3096. doi:10.1017/S032917140439
51. Burdick KE, Braga RJ, Goldberg JF, et al. Cognitive dysfunction in bipolar disorder: future place of pharmacotherapy. CNS Drugs. 2007;21(12):971-981. doi:10.2165/023210-2072120-02
52. Burdick KE, Endick CJ, Goldberg JF. Assessing cognitive deficits in bipolar disorder: are self-reports valid? Psychiatry Res. 2005;136(1):43-50. doi:10.1016/j.psychres.204.12.09
53. Martez-Ar A, Vieta E, Colom F, et al. Do cognitive complaints in euthymic bipolar patients reflect objective cognitive impairment? Psychother Psychosom. 2005;74(5):295-302. doi:10.159/086320
54. Nuechterlein KH, Green MF, Kern RS, et al. The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. Am J Psychiatry. 2008;165(2):203-213. doi:10.176/api.ajp.207.0701042
55. Kern RS, Gold JM, Dickinson D, et al. The MCCB impairment profile for schizophrenia outpatients: results from the MATRICS psychometric and standardization study. Schizophr Res. 2011;126(1-3):124-131. doi:10.1016/j.schres.2010.1.08
56. Kessler U, Schoeyen HK, Andreassen OA, et al. Neurocognitive profiles in treatment-resistant bipolar I and bipolar II disorder depression. BMC Psychiatry. 2013;13(1):105. doi:10.186/1471-24X-13-105
57. Yatham LN, Torres IJ, Malhi GS, et al. The International Society for Bipolar Disorders-Battery for Assessment of Neurocognition (ISBD-BANC). Bipolar Disord. 2010;12(4):351-363. doi:10.1/j.139-5618.2010.0830.x
58. Keefe RS, Fox KH, Davis VG, et al. The Brief Assessment of Cognition In Affective Disorders (BAC-A): performance of patients with bipolar depression and healthy controls. J Affect Disord. 2014;166:86-92. doi:10.1016/j.jad.2014.05.02
59. Goldberg TE, Goldman RS, Burdick KE, et al. Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect? Arch Gen Psychiatry. 2007;64(10):1115-1122. doi:10.101/archpsyc.64.10.15
60. Keefe RS, Fox KH, Harvey PD, et al. Characteristics of the MATRICS Consensus Cognitive Battery in a 29-site antipsychotic schizophrenia clinical trial. Schizophr Res. 2011;125(2-3):161-168. doi:10.1016/j.schres.2010.09.015
61. Mausbach BT, Harvey PD, Pulver AE, et al. Relationship of the Brief UCSD Performance-based Skills Assessment (UPSA-B) to multiple indicators of functioning in people with schizophrenia and bipolar disorder. Bipolar Disord. 2010;12(1):45-55. doi:10.1/j.139-5618.209.0787.x
62. Torrent C, Bonnin CM, Martez-Ar A, et al. Efficacy of functional remediation in bipolar disorder: a multicenter randomized controlled study. Am J Psychiatry. 2013;170(8):852-859. doi:10.176/api.ajp.2012.12070971
63. SolB, Bonnin CM, Mayoral M, et al; the CIBERSAM Functional Remediation Group. Functional remediation for patients with bipolar II disorder: Improvement of functioning and subsyndromal symptoms [published online ahead of print May 20, 2014]. Eur Neuropsychopharmacol. doi:10.1016/j.euroneuro.2014.05.010
64. Depp CA, Mausbach BT, Harmell AL, et al. Meta-analysis of the association between cognitive abilities and everyday functioning in bipolar disorder. Bipolar Disord. 2012;14(3):217-226. doi:10.1/j.139-5618.2012.0101.x
65. Calabrese JR, Keck PE Jr, Macfadden W, et al. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry. 2005;162(7):1351-1360. doi:10.176/api.ajp.162.7.1351